C omplex regional pain syndrome (CRPS) is a complication that may occur after surgery or trauma, but spontaneous development is also described. It was formerly known by many names, but was most commonly referred to as "reflex sympathetic dystrophy" (RSD).
The diagnosis of CRPS is based on signs and symptoms. Of the several diagnostic criteria sets available, the most commonly used are the Veldman et al, 1 the IASP, 2 and the "Budapest Criteria." 3 Most patients with CRPS have a burning spontaneous pain, disproportionate in intensity to the initial eliciting event, most often being a fracture of an extremity. 4 In the acute stages of CRPS, the affected limb is generally warmer than the contralateral limb, with edema as a common symptom. Hypohidrosis or hyperhidrosis is present in many patients. About 70% of the patients have weakness of all muscles in the affected region and a decrease in the active range of motion. The upper extremities are affected more frequently than the lower extremities. 5 The estimated overall incidence rate of CRPS is 26.2 per 100,000 person years. 5 Females are affected at least 3 times more often than males. The highest incidence occurs in females in the age category of 61 to 70 years. 5 It is reasonable to assume that different mechanisms are involved in a complex network of interactions, resulting in the painful and impairing disorder of CRPS. 6 CRPS often displays the classic aspects of inflammation. 1 There is convincing evidence that inflammation is one of the mechanisms playing a pivotal role in the pathophysiology of CRPS. 6 The presence of local inflammation was shown in a scintigraphic study on CRPS in which vascular permeability for macromolecules was demonstrated. 7 Increased systemic calcitonin gene-related peptide levels in patients with acute CRPS suggest neurogenic inflammation as a pathophysiologic mechanism. 8 Increased levels of the pro-inflammatory cytokines have been detected in fluid from artificially raised skin blisters in the involved extremity in comparison to the contralateral site; however, no correlation has been found between levels of proinflammatory cytokines and the characteristics or duration of the disease. [9] [10] [11] [12] This is an indication that inflammation explains a part, but not the whole picture of the pathophysiology.
Analysis of blister fluid with a multiplex array (testing for 25 different cytokines) revealed a pro-inflammatory expression profile, with increased markers for activated monocytes and macrophages. 13 Also, a pro-inflammatory cytokine expression profile was demonstrated in the cerebrospinal fluid of CRPS patients.
14 Venous blood of patients with CRPS showed elevated mRNA levels of the pro-inflammatory cytokines, tumor necrosis factor (TNF) and interleukin (IL)-2 and serum IL-2 protein, as well as a reduction of mRNA levels of the anti-inflammatory cytokines IL-4 and IL-10. 15 Plasma demonstrated higher levels of soluble TNF-a receptor. 16 After performing technetium 99m-anti-TNF-a antibody scintigraphy, a recent case report showed that TNF-a was only localized in the affected hands of patients with early CRPS. 17 In addition, the contribution of inflammation in the pathophysiology of CRPS is suggested by the successful reports from open-label studies on treatment with immunomodulating agents such as infliximab 18 and immunoglobulin. 19 Immunomodulating medication reduces the manifestation of inflammation by influencing mediators of inflammation, such as cytokines, neuropeptides, eicosanoids, and amino acids. If inflammation does play a role in the pathophysiology of CRPS, then immunomodulating medication may be beneficial for CRPS patients.
Despite the fact that, especially in higher doses, nonsteroidal anti-inflammatory drugs (NSAIDs) also show anti-inflammatory effects, these drugs are not included in the group of immunomodulating medications. For this reason, we excluded them from this review. In general we know that NSAIDs have no effect in the CRPS. 20 In the Netherlands there is some popularity for treating CRPS with free radical scavengers. 21 Due to a lack of convincing evidence for effectiveness, these drugs never gained general international acceptance. For this study we decided to exclude them. This review presents the current empirical evidence for the benefit of administering the most commonly used immunomodulating drugs in CRPS patients.
GLUCOCORTICOIDS
Glucocorticoids are anti-inflammatory that prevent phospholipid release and decrease eosinophil action and a number of other mechanisms. Interactions between the nervous system, the hypothalamic-pituitary-adrenal axis, and components of the innate and adaptive immune system play a key role in the regulation of inflammation and immunity. Glucocorticoids can also inhibit prostaglandin production through some independent mechanisms. 22 
TUMOR NECROSIS FACTOR-a ANTAGONISTS
Tumor necrosis factor alpha (TNF-a) is a cytokine that promotes an inflammatory response. Although principally produced by macrophages, other cells (including lymphocytes and mast cells), and tissue cells (such as epithelial cells and fibroblasts) can also secrete TNF. 23 The possible mechanism of action of anti-TNF agents are inhibition of inflammatory "cytokine cascade" mediated by TNF; sequestration of TNF by binding; complementmediated lysis of cells expressing TNF; altered leukocyte recruitment and endothelial activation; reduction of vascular endothelial growth factor expression and neovascularization; restoration of function of regulatory T cells, and induction of T lymphocyte apoptosis.
THALIDOMIDE
Thalidomide inhibits TNF-a production by human blood monocytes, without influencing either general protein synthesis or the expression of 3 other monocyte-derived cytokines. Thalidomide exerts a selective effect by suppressing only TNF-a secretion, neither IL-1b, IL-6, nor granulocyte macrophage colony-stimulating factor production is influenced by the drug. 24 Thalidomide was introduced as a sedative drug in the late 1950s. It was withdrawn from the market in the early 1960s due to teratogenicity and neuropathy. There is growing interest due to its immunomodulatory properties. Thalidomide is also a potent inhibitor of new blood vessel growth. 25 On the basis of this finding clinical trials were initiated, which have reported its effectiveness against multiple myeloma.
26

BISPHOSPHONATES
The most important biological effect of bisphosphonates is the reduction of bone remodeling through the inhibition of osteoclastic activity, but there is evidence of extra-skeletal biological effects of bisphosphonates. 27 Bisphosphonates exert their effects also on cells of the immune system with an "immunomodulating" effect, influencing the production of pro-inflammatory and antiinflammatory cytokines and changing the molecular expression involved in the immune process and anti-inflammatory response. The exact identification of target cells and interference mechanisms of bisphosphonates with the immune and inflammatory responses are not yet totally clear.
IMMUNOGLOBULINS
The mechanism of action of immunoglobulins involves modulation of expression and function of Fc receptors, interference with activation of complement and the cytokine network, provision of anti-idiotypic antibodies, regulation of cell growth, and effects on the activation, differentiation, and effector functions of dendritic cells, T and B cells. 28 Modulation of the production of cytokines and cytokine antagonists by intravenous immunoglobulin is a major mechanism by which immunoglobulin exerts its anti-inflammatory effects. The anti-inflammatory effects are not restricted to monocytic cytokines, but are also largely dependent on the ability of intravenous immunoglobulin to modulate Th1 and Th2 cytokine production.
MATERIALS AND METHODS
The The abstracts of retrieved articles were manually reviewed to assess suitability for inclusion using the following criteria: adult humans having CRPS (the previously used names for this syndrome were also allowed, eg, shoulder-hand syndrome, RSD), together with the use of one of the abovementioned immunomodulating medications. The references of the selected articles were also checked for additional relevant papers. Finally, from all studies fulfilling the inclusion criteria, the following information was examined: type of study, sample size, duration of disease, type and route of medication, primary outcome measures, and results
RESULTS
The literature search yielded 39 articles, 10 case reports, 19 observational studies, and 10 randomized controlled trials (RCTs: 7 blinded and 3 nonblinded). The results of the various medications are described below (and in Table 1 ).
Glucocorticoids
A total of 3 case reports, 13 open-label studies, and 5 RCTs (2 of which were blinded) were found. The 3 case 33, 39, 44 In the 13 open-label studies, various dose regimens were prescribed and different routes of administration were used. [29] [30] [31] [32] [34] [35] [36] 38, 40, 42, 43, 47, 48 In 3 of the open-label studies, patients who received medication were analyzed, as were those who received stellate ganglion blockade, physiotherapy, or no specific treatment. These treatments were then compared with each other. 30, 31, 36 Although the results of the open-label studies were based on different parameters, like clinical improvement and visual analog scale, the use of glucocorticoids seems to cause predominantly improvement in outcome. Only one of these studies described 2 major adverse events (arterial occlusion below the femorals and manic psychosis 30 ); in the remaining studies only minor events (eg, weight gain) were described.
Of the 5 RCTs 37,41,45,46,49 2 were double-blinded. 45, 49 The first double-blinded study showed no improvement of CRPS using a Bier block with methylprednisolone compared with placebo. 45 The second study, in which patients received medication intrathecally, was stopped early owing to no effect after interim analysis. 49 In 2 of the remaining 3 nonblinded RCTs, use of glucocorticoids resulted in a significantly greater improvement in activity of CRPS 37 or in shoulder-hand syndrome score 41 compared with placebo. The third RCT showed a significantly greater improvement in the signs and symptoms of CRPS among patients receiving glucocorticoid compared with those receiving piroxicam. 46 In 3 of the 5 RCTs, the patients with CRPS for a period of about 3 months. 37, 45, 46 In another study, patients has CRPS for a mean duration of 4.5 years, 49 and in 1 study the duration of disease was not reported. 41 The studies used different primary outcome measures. In 1 RCT, the placebo group could also receive medication afterwards (Table 1) . 41 In contrast to the open-label studies, no serious side-effects were described.
TNF-a antagonists
Two case reports were found describing 3 patients. 18, 50 All 3 patients received infliximab and showed improvement in pain, temperature, and motor function. The 2 patients who had CRPS for 2 to 3 months showed greater improvement than patients with CRPS for 5 years. No adverse effects were observed.
Thalidomide
Two case reports and 1 open-label study were found. In the case reports, thalidomide was introduced for CRPS patients with a comorbid condition. 51, 52 In this case thalidomide had a beneficial effect on CRPS. In the openlabel study 42 patients were treated. 53 A "dramatic response" occurred in 17% of the patients, and 14% experienced at least modest pain relief and/or showed some reduction in the need for concurrent medications. No results for the remainder of the patients were reported.
In 1 patient, due to persistent paresthesia, thalidomide was temporarily stopped after which the pain re-occurred. 52 Although patients often felt worse during the first weeks of therapy (eg, increased pain and edema) no major sideeffects were reported.
Bisphosphonates
Two case reports, 4 open-label studies, and 4 doubleblind RCTs were found. In the case reports the 2 patients experienced pain relief. 58, 63 In the open-label studies pamidronate or ibandronate was used. 54, 55, 59, 62 These studies reported a positive effect of both drugs on pain intensity.
Patients who participated in the RCTs were prescribed alendronate (oral or intravenous), 56, 61 clonadrate, 57 or pamidronate. 60 All were compared with placebo. In 2 of the RCTs, patients had CRPS for less than 6 months, 56, 57 compared with about 7 months to 6 years in the other 2 studies. 60, 61 In all RCTs there was a significant decrease of pain. Apart from pain, the other primary outcome measures were different but all showed improvement. Three RCTs were followed by an open-label study in which continuation of the medication showed an additional effect; however, the difference was not significant. 56, 57, 61 Side-effects were minimal (eg, transitory flu-like symptoms); 1 patient dropped-out of one of the trials due to upper gastrointestinal intolerance. 61 No serious adverse events were described.
Immunoglobulin
The search yielded 1 case report, 1 open-label study, and 1 double-blinded RCT. In the case report the patient recorded more than 50% pain reduction, accompanied by cessation of autonomic signs. 19 In the open-label study, only 11 of the 130 described patients were had CRPS, 64 in the total group of patients, 20% had more than 70% pain relief, and 27.7% reported pain relief ranging from 25% to 70% relief.
The RCT was a double-blind, randomized, placebocontrolled study. 65 Patients received either the intervention in the first period and placebo in the second, or placebo in the first period and the intervention in the second. Pain intensity was the primary outcome measure and was 1.55 units lower after treatment with immunoglobulins compared with placebo. The treatment was associated with very few adverse events, except for moderate or severe headache and transient pain increase. No serious adverse events were reported.
DISCUSSION
This literature review was conducted to assess empirical evidence for the efficacy of various immunomodulating medication in CRPS patients. The assessment is complicated by the fact that the cited studies show extensive methodological variability, that is, presence or absence of a control group, use of different designs, and varying sample compositions, diagnostic criteria, and primary outcome measures. The exact impact of the outcome is often unclear.
The CRPS criteria applied for diagnosis vary between studies. The most common criteria are the IASP criteria, 66 a revision of the criteria set has been proposed for both diagnostic and research purposes. 67 Because different criteria for diagnosing CRPS were used in the studies in this review, it is unlikely that all patients in these studies are comparable.
The studies covered the treatment of both acute and chronic conditions. A scintigraphic study to investigate whether inflammatory characteristics were present showed significantly more patients with early CRPS (existing for r5 mo) with a positive scintigraphy compared with patients who had CRPS for a longer period. 7 Also, although the presence of local inflammation was confirmed in the first 2 years of CRPS, cytokine levels did not correlate with either the characteristics or duration of the disease. 10 Therefore, the acute versus chronic classification is probably inadequate, and the time factor thus becomes less important.
It seems difficult to determine the appropriate period for treatment with immunomodulating medication. It is more important to determine in each patient whether or not there is still an (ongoing) inflammatory process. In addition, different primary outcome measures were used in the studies. In none of the studies was an improvement in inflammation measured. We suggest that a selection of 2 or 3 representatives from the inflammatory cytokines panel, the Th1/Th2 cytokines panel and the chemokines panel would be sufficient to indicate the activity of the CRPS disease; during the course of the disease, this selected panel could also be used to indicate the effectiveness of therapeutic intervention. 13 This might allow to better determine which patients are likely to benefit from treatment with immunomodulating drugs.
Because the studies have different designs, the degree of empirical evidence yielded also differs. Most of the included articles were case reports or uncontrolled openlabel studies. On the basis of these studies, TNF-a antagonists and thalidomide were reported to have a positive effect. Noteworthy, an open-label study, in which CRPS patients received lenalidomide (a thalidomide analog), showed that lenalidomide's pain and functional improvement sustained over 52 weeks of treatment. There would be some serious adverse events, suspected to be related to lenalidomide. However, this study only appeared in a poster presentation at a congress, and these results have not been published. 68 The immunoglobulins were also investigated by means of a randomized double-blind placebo-controlled trial; this trial also showed a positive effect, albeit a small one. However, for the glucocorticoids and bisphosphonates, more RCTs have been performed. The glucocorticoids yielded 5 RCTs, of which the 2 blinded RCTs showed no benefit. However, a disadvantage is that the intervention in these 2 latter studies was administered by means of a Bier block, or intrathecally. In contrast, in the nonblinded trials, the oral glucocorticoids had a positive effect. Oral and intravenous bisphosphonates also appeared to have a positive effect. In our opinion, the use of bisphosphonates can be recommended; however, which medication, which dose, and for how long remains unclear. Our recommendation is in contrast to another group that also reviewed the 4 RCTs of bisphosphonates, 69 they concluded that, although bisphosphonates have the potential to reduce pain, there is insufficient evidence to recommend their use.
In summary, there is increasing evidence to show that inflammation does play a role in the pathophysiology of CRPS. Immune involvement brings a mechanism-based treatment within reach. On the basis of the results of this review, the use of immunomodulating medication may counteract the ongoing inflammation and might be an important step in the recovery of the disabled hand or foot. However, as might be evident from the studies described above, this literature is of a very poor quality. Therefore, there is a need for more high-quality intervention studies.
